Esperion Therapeutis.Inc. buy Piper Sandler
Start price
25.11.25
/
50%
€3.00
Target price
25.11.26
€7.81
Performance (%)
9.47%
Price
12.12.25
€3.28
Summary
This prediction is currently active. With a performance of 9.47%, the BUY prediction by Piper_Sandler for Esperion Therapeutis.Inc. is trending in the right direction. This prediction currently runs until 25.11.26. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Esperion Therapeutis.Inc. | 2.657% |
| iShares Core DAX® | 0.734% |
| iShares Nasdaq 100 | -2.686% |
| iShares Nikkei 225® | -2.261% |
| iShares S&P 500 | -1.346% |
Comments by Piper_Sandler for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat